Clinical Trials

46 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07393555 2026-02-06

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

117 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07298148 2026-01-21

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07355205 2026-01-21

FLINN

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07353476 2026-01-20

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07343479 2026-01-15

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

45 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07336732 2026-01-14

KANNON-5

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07333651 2026-01-12

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

90 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT07314216 2026-01-06

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07247786 2025-12-30

MIGRANT

68 enrolled

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07293247 2025-12-22

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

164 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07294261 2025-12-19

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07283198 2025-12-15

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06882174 2025-12-08

TIME-NSCLC

58 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07253142 2025-12-02

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07235306 2025-11-19

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07204548 2025-10-02

IVO Lung

63 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07200947 2025-10-01

QL1706

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07193160 2025-09-25

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07177092 2025-09-16

SURGAN-TKI

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07177105 2025-09-16

SURGAN-ICI

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07164170 2025-09-10

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

86 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07158840 2025-09-08

AGA TKI NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07158489 2025-09-05

ORIGIN2

47 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07138755 2025-08-24

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

35 enrolled